Compare Novavax Inc (NVAX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Waste Management, Inc. — how do they compare? Novavax Inc trades at $7.93 (market cap $1.31B), while Waste Management, Inc. trades at $227.39 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 69.2× Novavax Inc's market cap, and Waste Management, Inc. pays a 1.56% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | WM | |
|---|---|---|
Market Cap | $1.31B | $90.68B |
Sector | Health | Industrials |
52-Week High | $11.19 | $246.51 |
52-Week Low | $6.22 | $196.77 |
Enterprise Value | $889.30M | $113.47B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
WM trades at $227.2, up 0.26% on the day, with a neutral technical signal and strong analyst support. The company reported Q2 2026 EPS of $2.02, beating estimates, and maintains robust profitability with a net income margin of 11.12%. Revenue growth is steady, reaching $25.20B in 2025, though valuation multiples like a P/E of 59.74 appear elevated. Recent news highlights institutional trading activity and earnings focus on pricing discipline.
The outlook is positive with a consensus price target of $263.43, implying 16% upside, supported by 57% buy ratings. Risks include high debt levels and sensitivity to economic cycles, but consistent cash flow generation and margin gains provide a solid foundation for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
